Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focusing on developing medicines for hypertension, chronic kidney disease (CKD), and aldosterone-related disorders, has announced its plan to release second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the call via domestic (1-877-407-9127) or international (1-201-689-8574) phone numbers, or through a webcast link available on the company's Investor Relations webpage.

News Market Reaction – MLYS

+0.09%

+0.09% Session move

In the trading session that priced this news, MLYS gained 0.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024.

Tuesday, August 13th @ 4:30 p.m. ET
Domestic:	1-877-407-9127
International:	1-201-689-8574
Webcast:	Link

A live webcast of the conference call may be found here or on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When will Mineralys Therapeutics (MLYS) release its Q2 2024 financial results?

Mineralys Therapeutics (MLYS) will release its second quarter 2024 financial results on Tuesday, August 13, 2024, after the financial markets close.

What time is Mineralys Therapeutics' (MLYS) Q2 2024 earnings call scheduled for?

Mineralys Therapeutics' (MLYS) Q2 2024 earnings conference call is scheduled for Tuesday, August 13, 2024, at 4:30 p.m. ET.

How can investors access Mineralys Therapeutics' (MLYS) Q2 2024 earnings call?

Investors can access Mineralys Therapeutics' (MLYS) Q2 2024 earnings call via phone (1-877-407-9127 for domestic, 1-201-689-8574 for international) or through a webcast link available on the company's Investor Relations webpage.

What are the main therapeutic areas Mineralys Therapeutics (MLYS) focuses on?

Mineralys Therapeutics (MLYS) focuses on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone.